Bruno Benites

Dr. Bruno Benites

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Vaccine
Verified
Journal Article
Closed access
BBBruno Benites
Bruno Benites
ADAdriana da Silva Santos Duarte
Adriana da Silva Santos Duarte
ALAna Leda Figueiredo Longhini
Ana Leda Figueiredo Longhini
ISIrene Santos
Irene Santos
MAMarisa Claudia Alvarez
Marisa Claudia Alvarez
SSSara Teresinha Olalla Saad
Sara Teresinha Olalla Saad

3 September 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
BBBruno Benites
Bruno Benites
TBThais Celi Lopes Benevides
Thais Celi Lopes Benevides
IVIsabella Salvetti Valente
Isabella Salvetti Valente
JMJose Francisco Marques
Jose Francisco Marques
SGSimone Cristina Olenscki Gilli
Simone Cristina Olenscki Gilli
SSSara Teresinha Olalla Saad
Sara Teresinha Olalla Saad

16 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
BBBruno Benites
Bruno Benites
MPMARISA DE PRAX
MARISA DE PRAX
SSSARA Teresinha OLALLA SAAD
SARA Teresinha OLALLA SAAD
Dendritic cells play a fundamental role in the antitumor immunity cycle, and the loss of their antigen-presenting function is a recognized mechanism of tumor evasion. We have recently demonstrated the effect of exosomes extracted from serum of patients with acute myeloid leukemia as important inducers of dendritic cell immunotolerance, and several other works have recently demonstrated the effects of these nanoparticles on immunity to other tumor types as well. The aim of this review was to highlight the recent findings on the effects of tumor exosomes on dendritic cell functions, the mechanisms by which they can lead to tumor evasion, and their manipulation as a possible strategy in cancer treatment.

1 July 2016 in Experimental Hematology
Verified
Journal Article
Closed access
SGSimone Cristina Olenscki Gilli
Simone Cristina Olenscki Gilli
FPFernando Vieira Pericole
Fernando Vieira Pericole
BBBruno Benites
Bruno Benites
ESEmilia Sippert
Emilia Sippert
LCLilian Maria Castilho
Lilian Maria Castilho
SSSara Teresinha Olalla Saad
Sara Teresinha Olalla Saad

28 May 2016 in Hematology
Verified
Journal Article
Closed access
BBBruno Benites
Bruno Benites
SBStephany Oliveira Bastos
Stephany Oliveira Bastos
GBGabriel Baldanzi
Gabriel Baldanzi
ASAllan de Oliveira dos Santos
Allan de Oliveira dos Santos
CRCelso Dario Ramos
Celso Dario Ramos
SSSara Teresinha Olalla Saad
Sara Teresinha Olalla Saad
Objectives: In sickle cell/β-thalassemia, mutations in the corresponding β-globin genes are responsible for complex pathological events resulting in diverse clinical complications. The objective of this study was to provide an overview of the clinical and laboratory characteristics of patients with the syndrome, and of the degree of severity of clinical manifestations resulting from the β-thalassemia mutation. Methods: A retrospective chart review was performed on 46 patients with sickle cell/β-thalassemia (31 Sβ° and 15 Sβ+), evaluating hematological parameters and end organ damage. Statistical analyzes were carried out in order to highlight differences between the two groups according to the nature of the thalassemia mutation. Results: As expected, patients with the Sβ0 phenotype had a higher degree of hematological involvement in comparison to Sβ+ patients; with lower hemoglobin levels, and signs of more intense chronic hemolysis. However, Sβ+ patients were more prone to the occurrence of acute chest syndrome. The impact of the thalassemia mutation upon total body and bone composition was also evident, as Sβ0 patients presented lower body mass index (BMI) and bone mineral density. The degree of bone damage correlated to lower BMI and hemoglobin levels, as well as plaquetosis, monocytosis and elevated lactate dehydrogenase, possibly reflecting the effects of hemolysis and inflammation upon bone metabolism and body constitution. Conclusions: This study identified significant differences among sickle cell/β-thalassemia patients according to the beta mutation involvement, pointing to an important predictor of disease severity.

15 June 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
CBCaroline C. B. Braga
Caroline C. B. Braga
BBBruno Benites
Bruno Benites
DADulcineia M. de Albuquerque
Dulcineia M. de Albuquerque
MAMarisa C. Alvarez
Marisa C. Alvarez
TSTiago Seva‐Pereira
Tiago Seva‐Pereira
SSSara T. O. Saad
Sara T. O. Saad
Key Clinical Message: This manuscript describes the case of a patient with sickle cell anemia who died of fulminant hepatitis after therapy with the iron chelator Deferasirox. The patient was homozygous for the −1774delG polymorphism in the Abcc2 gene, which raises the concern about the use of hepatotoxic drugs in this specific context.